Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomised controlled trials
Background<br/> Platelet dysfunction, including that caused by antiplatelet agents, increases the risk of peri-operative bleeding. The optimal management of patients with platelet dysfunction undergoing surgery is unclear. <br/><br/>Objectives<br/> To assess whether desmopres...
Autors principals: | Desborough, M, Oakland, K, Crivellari, M, Doree, C, Estcourt, L, Stanworth, S |
---|---|
Format: | Journal article |
Publicat: |
Wiley
2017
|
Ítems similars
-
Desmopressin use for minimising perioperative blood transfusion
per: Desborough, M, et al.
Publicat: (2017) -
Desmopressin for treatment of thrombocytopenia or platelet dysfunction
per: Desborough, MJR
Publicat: (2017) -
Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial
per: Desborough, M, et al.
Publicat: (2019) -
Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial
per: Michael J R Desborough, et al.
Publicat: (2020-11-01) -
Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
per: Estcourt, L, et al.
Publicat: (2015)